{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:17:49Z","timestamp":1790115469694,"version":"4.0.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.anai.2026.06.006","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T17:47:08Z","timestamp":1781459228000},"page":"291-299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Precision medicine in atopic dermatitis"],"prefix":"10.1016","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4381-1861","authenticated-orcid":false,"given":"Luz","family":"Fonacier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Mawhirt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Roellke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2026.06.006_bib0001","series-title":"Immunotherapies for Allergic Disease","author":"Cox","year":"2019"},{"issue":"3","key":"10.1016\/j.anai.2026.06.006_bib0002","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","article-title":"Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE\u2013 and Institute of Medicine\u2013based recommendations","volume":"132","author":"Chu","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"12","key":"10.1016\/j.anai.2026.06.006_bib0003","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra2023911","article-title":"Atopic dermatitis","volume":"384","author":"Stander","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2026.06.006_bib0004","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1248\/bpb.b19-00088","article-title":"Current understanding of pathophysiological mechanisms of atopic dermatitis: interactions among skin barrier dysfunction, immune abnormalities and pruritus","volume":"43","author":"Fujii","year":"2020","journal-title":"Biol Pharm Bull"},{"issue":"6","key":"10.1016\/j.anai.2026.06.006_bib0005","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2025-071812","article-title":"Atopic dermatitis: update on skin-directed management: clinical report","volume":"155","author":"Schoch","year":"2025","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.anai.2026.06.006_bib0006","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.3390\/ijms21041314","article-title":"The role of TH17-related cytokines in atopic dermatitis","volume":"21","author":"Sugaya","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.anai.2026.06.006_bib0007","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/jdv.18225","article-title":"Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options","volume":"36","author":"Bieber","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10478","key":"10.1016\/j.anai.2026.06.006_bib0008","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(24)02519-4","article-title":"Atopic dermatitis","volume":"405","author":"Guttman-Yassky","year":"2025","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.anai.2026.06.006_bib0009","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.jaci.2021.10.022","article-title":"Advances in atopic dermatitis in 2019-2020: endotypes from skin barrier, ethnicity, properties of antigen, cytokine profiles, microbiome, and engagement of immune cells","volume":"148","author":"Nomura","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2026.06.006_bib0010","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jaci.2025.02.029","article-title":"Endotypes of atopic dermatitis","volume":"156","author":"Fyhrquist","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2026.06.006_bib0011","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jaad.2022.12.029","article-title":"Guidelines of care for the management of atopic dermatitis in adults with topical therapies","volume":"89","author":"Sidbury","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2026.06.006_bib0012","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2026.06.006_bib0013","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jaci.2023.08.030","article-title":"Topical treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials","volume":"152","author":"Chu","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2026.06.006_bib0014","article-title":"Strategies for using topical corticosteroids in children and adults with eczema","volume":"3","author":"Lax","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.anai.2026.06.006_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2005.01.010","article-title":"Adverse effects of topical glucocorticosteroids","volume":"54","author":"Hengge","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2026.06.006_bib0016","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.jaci.2014.03.003","article-title":"Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology","volume":"133","author":"Khattri","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2026.06.006_bib0017","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.3390\/jcm12041390","article-title":"Efficacy and safety of low-dose cyclosporine relative to immunomodulatory drugs used in atopic dermatitis: a systematic review and meta-analysis","volume":"12","author":"Kim","year":"2023","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.anai.2026.06.006_bib0018","article-title":"Systemic treatments for eczema: a network meta-analysis","volume":"9","author":"Sawangjit","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.anai.2026.06.006_bib0019","article-title":"Effects of dupilumab on quality of life in patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Sun","year":"2025","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.anai.2026.06.006_bib0020","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/DER.0000000000000845","article-title":"Systemic therapy for atopic dermatitis in older adults and adults with comorbidities: a scoping review and international eczema council survey","volume":"33","author":"Drucker","year":"2022","journal-title":"Dermatitis"},{"issue":"6","key":"10.1016\/j.anai.2026.06.006_bib0021","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jaci.2023.08.029","article-title":"Systemic treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials","volume":"152","author":"Chu","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2026.06.006_bib0022","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","article-title":"Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis","volume":"84","author":"Halling","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"20","key":"10.1016\/j.anai.2026.06.006_bib0023","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.3390\/jcm12206575","article-title":"Predictive factors of early response to dupilumab in patients with moderate-to-severe atopic dermatitis","volume":"12","author":"Ferrucci","year":"2023","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.anai.2026.06.006_bib0024","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jaad.2022.12.052","article-title":"Baseline skin cytokine profiles determined by RNA in situ hybridization correlate with response to dupilumab in patients with eczematous dermatitis","volume":"88","author":"Singh","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2026.06.006_bib0025","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/bjd\/ljad032","article-title":"Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab","volume":"188","author":"Wu","year":"2023","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2026.06.006_bib0026","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2026.06.006_bib0027","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.19573","article-title":"Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2026.06.006_bib0028","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.3390\/jcm14062077","article-title":"Effectiveness of tralokinumab across atopic dermatitis phenotypes","volume":"14","author":"Barei","year":"2025","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.anai.2026.06.006_bib0029","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1111\/all.16108","article-title":"Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years","volume":"79","author":"Guttman-Yassky","year":"2024","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.anai.2026.06.006_bib0030","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjd.21867","article-title":"Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials","volume":"187","author":"Simpson","year":"2022","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.anai.2026.06.006_bib0031","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","article-title":"Two Phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.anai.2026.06.006_bib0032","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/jamadermatol.2022.5534","article-title":"Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere)","volume":"159","author":"Simpson","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.anai.2026.06.006_bib0033","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1007\/s13555-025-01481-4","article-title":"Lebrikizumab rapidly lowers inflammatory biomarkers with clinical correlations in moderate-to-severe atopic dermatitis","volume":"15","author":"Guttman-Yassky","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"10.1016\/j.anai.2026.06.006_bib0034","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/bjd\/ljad022","article-title":"Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials","volume":"188","author":"Blauvelt","year":"2023","journal-title":"Br J Dermatol"},{"issue":"10451","key":"10.1016\/j.anai.2026.06.006_bib0035","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0140-6736(24)01203-0","article-title":"Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials","volume":"404","author":"Silverberg","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.anai.2026.06.006_bib0036","doi-asserted-by":"crossref","DOI":"10.1111\/exd.70120","article-title":"Nemolizumab improves pruritus in patients with intrinsic atopic dermatitis lacking atopic predisposition: a single-centre pilot retrospective cohort study","volume":"34","author":"Sato","year":"2025","journal-title":"Exp Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2026.06.006_bib0037","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","article-title":"Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies","volume":"90","author":"Davis","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.anai.2026.06.006_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1365544","article-title":"Total eosinophil count as a biomarker for therapeutic effects of upadacitinib in atopic dermatitis over 48 weeks","volume":"15","author":"Hagino","year":"2024","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.anai.2026.06.006_bib0039","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/all.15969","article-title":"Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitis","volume":"79","author":"Guttman-Yassky","year":"2024","journal-title":"Allergy"},{"issue":"7","key":"10.1016\/j.anai.2026.06.006_bib0040","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/ijd.70228","article-title":"Upadacitinib leads in efficacy: a Bayesian network meta-analysis of four JAK inhibitors in moderate-to-severe atopic dermatitis","volume":"65","author":"Babul","year":"2026","journal-title":"Int J Dermatol"},{"issue":"10348","key":"10.1016\/j.anai.2026.06.006_bib0041","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","article-title":"Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial","volume":"400","author":"Reich","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.anai.2026.06.006_bib0042","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/00128071-200506020-00001","article-title":"Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis","volume":"6","author":"Breuer","year":"2005","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2026.06.006_bib0043","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/09546630701287332","article-title":"Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis","volume":"18","author":"Fleischer","year":"2007","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.anai.2026.06.006_bib0044","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jaad.2017.11.056","article-title":"Phosphodiesterase 4 inhibitors","volume":"78","author":"Zebda","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2026.06.006_bib0045","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jaci.2019.06.047","article-title":"Crisaborole and atopic dermatitis skin biomarkers: an intrapatient randomized trial","volume":"144","author":"Bissonnette","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.anai.2026.06.006_bib0046","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/jamadermatol.2024.3121","article-title":"Roflumilast cream, 0.15%, for atopic dermatitis in adults and children: INTEGUMENT-1 and INTEGUMENT-2 randomized clinical trials","volume":"160","author":"Simpson","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"8","key":"10.1016\/j.anai.2026.06.006_bib0047","article-title":"Topical anti-inflammatory treatments for eczema: network meta-analysis","volume":"8","author":"Lax","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.anai.2026.06.006_bib0048","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaad.2020.10.085","article-title":"Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent","volume":"84","author":"Bissonnette","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.anai.2026.06.006_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2025.117559","article-title":"Dual activation of AhR and Nrf2 pathways by the natural stilbenoid tapinarof protects against particulate matter-induced skin barrier dysfunction","volume":"505","author":"Lin","year":"2025","journal-title":"Toxicol Appl Pharmacol"},{"issue":"3","key":"10.1016\/j.anai.2026.06.006_bib0050","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaad.2024.05.023","article-title":"Tapinarof cream 1% once daily: significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials","volume":"91","author":"Silverberg","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2026.06.006_bib0051","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jaad.2023.04.029","article-title":"Efficacy, safety, and treatment patterns of Ruxolitinib 1.5% cream in adult atopic dermatitis: a single center retrospective study","volume":"89","author":"Stefanko","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"10451","key":"10.1016\/j.anai.2026.06.006_bib0052","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(24)01027-4","article-title":"Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials","volume":"404","author":"Bissonnette","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.anai.2026.06.006_bib0053","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jaad.2025.03.008","article-title":"Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials","volume":"93","author":"Gooderham","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.anai.2026.06.006_bib0054","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1097\/MS9.0000000000003771","article-title":"Delgocitinib 2% cream: a promising FDA-approved therapy for moderate-to-severe chronic hand eczema","volume":"87","author":"Jawaid","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"issue":"6","key":"10.1016\/j.anai.2026.06.006_bib0055","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"10086","key":"10.1016\/j.anai.2026.06.006_bib0056","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (Liberty AD Chronos): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.anai.2026.06.006_bib0057","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti\u2013IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2026.06.006_bib0058","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of Ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"suppl","key":"10.1016\/j.anai.2026.06.006_bib0059","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2133.2004.06269.x","article-title":"The role of topical calcineurin inhibitors in atopic dermatitis","volume":"151","author":"Alomar","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2026.06.006_bib0060","article-title":"Ruxolitinib cream has dual efficacy on pruritus and inflammation in experimental dermatitis","volume":"11","author":"Scuron","year":"2020","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.anai.2026.06.006_bib0061","first-page":"1092","article-title":"TH17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways","volume":"159","author":"Nograles","year":"2008","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2026.06.006_bib0062","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial","volume":"78","author":"Guttman-Yassky","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2026.06.006_bib0063","first-page":"264","article-title":"New non-steroidal topical therapies for inflammatory dermatoses-part 3: Roflumilast","volume":"21","author":"DiRuggiero","year":"2023","journal-title":"Skinmed"},{"issue":"3","key":"10.1016\/j.anai.2026.06.006_bib0064","first-page":"177","article-title":"New non-steroidal topical therapies for inflammatory dermatoses-part 2: Tapinarof","volume":"21","author":"DiRuggiero","year":"2023","journal-title":"Skinmed"},{"issue":"5","key":"10.1016\/j.anai.2026.06.006_bib0065","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s11882-013-0371-y","article-title":"Non-pharmacologic therapies for atopic dermatitis","volume":"13","author":"Lio","year":"2013","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.anai.2026.06.006_bib0066","article-title":"Topical integrative treatment for pruritus: a comprehensive review","author":"Park","year":"2025","journal-title":"J Int Derm"},{"issue":"9","key":"10.1016\/j.anai.2026.06.006_bib0067","doi-asserted-by":"crossref","first-page":"977","DOI":"10.36849\/JDD.6705","article-title":"Efficacy, safety, and applications of skin protectants","volume":"21","author":"Patel","year":"2022","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.anai.2026.06.006_bib0068","first-page":"17","article-title":"Non-pharmacologic and lifestyle-based approaches to managing chronic hand eczema: a narrative review","author":"Maher","year":"2025","journal-title":"Derma Dig"},{"key":"10.1016\/j.anai.2026.06.006_bib0069","article-title":"The effect of biologics on the cutaneous microbiome in atopic dermatitis: a review","author":"Lewin","year":"2025","journal-title":"J Integ Derm"},{"issue":"11","key":"10.1016\/j.anai.2026.06.006_bib0070","first-page":"16","article-title":"Reaching for the stars in atopic dermatitis: efficacy, safety, tolerability, accessibility, and remission\/Remittive effects (ESTAR)","volume":"18","author":"An","year":"2025","journal-title":"J Clin Aesthet Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2026.06.006_bib0071","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.iac.2016.08.008","article-title":"Current and future biomarkers in atopic dermatitis","volume":"37","author":"Thijs","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"issue":"7","key":"10.1016\/j.anai.2026.06.006_bib0072","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s13555-024-01193-1","article-title":"Biomarkers in atopic dermatitis","volume":"14","author":"Libon","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"10.1016\/j.anai.2026.06.006_bib0073","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.jaci.2023.01.019","article-title":"Biomarkers in atopic dermatitis","volume":"151","author":"Bakker","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2026.06.006_bib0074","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jaci.2025.01.013","article-title":"Update on atopic dermatitis","volume":"155","author":"Meledathu","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2026.06.006_bib0075","article-title":"Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis","volume":"3","author":"Rewerska","year":"2024","journal-title":"J Allergy Clin Immunol Glob"},{"issue":"10372","key":"10.1016\/j.anai.2026.06.006_bib0076","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0140-6736(22)02037-2","article-title":"An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study","volume":"401","author":"Guttman-Yassky","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.anai.2026.06.006_bib0077","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1111\/all.16183","article-title":"Integrating multi-omics approaches in deciphering atopic dermatitis pathogenesis and future therapeutic directions","volume":"79","author":"Nakajima","year":"2024","journal-title":"Allergy"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626002668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626002668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:49:32Z","timestamp":1788256172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120626002668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1081120626002668"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2026.06.006","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision medicine in atopic dermatitis","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2026.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}